Century Therapeutics, Inc.
IPSC · XNASCIK 1850119fmd_02SYGVP0Y6MK55G6A5J0SRREMMManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | 5 | 2 | 7 | 109 |
| Research and development | 40 | 76 | 97 | 93 | 107 | 96 |
| Total operating expenses | 54 | 95 | 139 | 149 | 145 | 126 |
| Operating income | (54) | (95) | (134) | (147) | (138) | (17) |
| Interest expense | 0 | 1 | 1 | 1 | – | – |
| Other non-operating income (expense) | 0 | (1) | 3 | 12 | 13 | 8 |
| Income before taxes | (54) | (96) | (131) | (135) | (125) | (10) |
| Income tax expense | – | 0 | 0 | 2 | 2 | (0) |
| Net income from continuing operations | – | (96) | (131) | (137) | (127) | (10) |
| Net income | (54) | (96) | (131) | (137) | (127) | (10) |